Ascendia is a specialty CDMO with nanotechnology platforms, dedicated to enabling formulations for pre-clinical and clinical stage drug candidates and developing enhanced formulations of existing drug products.
Ascendia provides state-of-the-art formulation development services for NCE and repurposing 505b2 drugs, especially insoluble molecules, and early phase cGMP manufacture of clinical trial materials. Applying its nano-particle technologies and expertise, Ascendia can rapidly assess the feasibility of a broad array of formulation options in order to improve a drug’s solubility and bioavailability.
Our technologies include nano-emulsions, amorphous solid dispersions, oral controlled release, self-emulsifying drug delivery systems (SEDDs) and production of nano-particles. Ascendia provides development and testing services – from pre-formulation through to clinical phase 1, phase 2 manufacture of clinical supplies.